Two-step strategy for the identification of SARS-CoV-2 variants co-occurring with spike deletion H69-V70, Lyon, France, August to December 2020

Antonin Bal*[1,2], Gregory Destras*[1,2], Alexandre Gaymard*[1,2], Hadrien Regue[1], Quentin Semanas[1], Constance d'Aubarede[3], Geneviève Billaud[1,2], Frédéric Laurent[4,5], Claudia Gonzalez[1], Martine Valette[1], Maude Bouscambert[1], Bruno Lina[1,2], Florence Morfin[1,2], Laurence Josset [1,2] and the COVID-Diagnosis HCL Study Group

[1]Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France.

[2] CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.

[3] Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France

[4] CIRI - Centre International de Recherche en Infectiologie, Team Pathogenesis of staphylococcal infections Inserm U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Lyon, France.

[5]Laboratoire de Bactériologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.

Corresponding author: Laurence Josset, Pharm.D, Ph.D
Associate Professor
Lyon 1 University
Hospices Civils de Lyon, France
National reference center for respiratory viruses
Phone: +33 (0)4 72 12 96 47
Email: laurence.josset@chu-lyon.fr
*****equal contribution

Keywords: SARS-CoV-2; COVID-19, whole genome sequencing; spike protein, variants, deletion

Abstract

The spike deletion H69-V70 (ΔH69/ΔV70) has been recently detected in a SARS-CoV-2 variant under investigation in England (VUI 202012/01) as well as in cluter-5 variant detected both in minks and humans in Denmark. Herein we report the implementation of a two-step strategy enabling to detect SARS-CoV-2 variants carrying H69-V70 deletion. We found that this deletion resulted in a false negative result for the spike target of a three-target RT-PCR assay (TaqPath kit). From August 3rd to December 20th, 59/9,266 (0.6%) of positive tests displayed a S negative profile (negative for S target and positive for N & ORF1ab targets). Among the 59 samples without detection of the S target, 36 were available for whole genome sequencing (WGS). The most frequent S mutations co-occurring with ΔH69/ΔV70 were S477N & D614G (21/36 samples). The co-occurrence of N439K and D614G mutations was found in 10/36 samples. The complete combination of S mutations detected in VUI 202012/01 or in cluster-5 variant was not found. The data presented herein emphasize that the TaqPath RT-PCR assay enables a rapid, large-scale screening of ΔH69/ΔV70 variants. Samples with S negative profiles should be further addressed to national referral laboratories for SARS-CoV-2 WGS. This 2-step strategy is currently being reinforced in France as national diagnostic platforms have mainly implemented the TaqPath RT-PCR kit.

Since September a SARS-CoV-2 spike (S) deletion H69-V70 (ΔH69/ΔV70) has attracted increasing attention. This deletion was part of the mutations detected in the cluster-5 variant identified both in minks and humans in Denmark. This cluster-5 variant carries a receptor binding domain (RBD) mutation Y453F and was associated with reduced susceptibility to neutralizing antibodies to sera from recovered COVID-19 patients [1–3]. The ΔH69/ΔV70 has also co-occurred with two other RBD mutations of increasing interest [4]: N439K that is currently spreading in Europe and might also have reduced susceptibility to SARS-CoV-2 antibodies [5]; and N501Y that is part of the SARS-CoV-2 variant under investigation (VUI) 202012/01 recently detected in England [6]. Although the impact of ΔH69/ΔV70 on SARS-CoV-2 pathogenesis is not clear, enhanced surveillance is urgently needed. Herein we report the implementation of a two-step strategy enabling to detect VUI 202012/01 or other variants carrying ΔH69/ΔV70 deletion.

ΔH69/ΔV70 associated with S gene detection failure of a three-target RT-PCR assay

As part of routine SARS-CoV-2 genomic surveillance performed at the national reference center for respiratory viruses (Lyon, France) [7], a 6-nucleotide deletion (21765-21770) within the S gene was identified in two nasopharyngeal samples collected on September 1st and 7th , respectively. The SARS-CoV-2 infection diagnosis had been performed with the Applied Biosystems TaqPath RT-PCR COVID-19 kit (Thermo Fisher Scientific, Waltham, USA) that includes the ORF1ab, S, and N gene targets. For these two samples, the S target was negative while ORF1ab and N targets were positive with Ct values < 25 (Figure 1A).

The mean coverage for the whole genome sequences generated was 6903x and 6898x, respectively and the S deletion 21765-21770 was present in 100% of the reads. Using CoV-GLUE online resource [8], we found that the S deletion 21765-21770 led to the removal of 2 amino acids (ΔH69/ΔV70) in the N-terminal domain of the S1 subunit of the S protein (Figure 1B). The whole genome sequencing (WGS) method used was the amplicon-based

ARTIC v3 protocol (https://artic.network/ncov-2019) combined with Nextera DNA Flex library and sequencing on NextSeq 500 platform (Illumina, San Diego, USA). To confirm the presence of the deletion, one sample was also sequenced with an untargeted metagenomic protocol that yielded the same sequence. Of note, this metagenomic approach could not be applied for the second sample due to low viral load [9].

Although the coordinates of the primer/probe binding regions were not available for the TaqPath kit, the manufacturer confirmed that the S deletion H69-V70 was in the area targeted by the test.

ΔH69/ΔV70 screening with RT-PCR followed by WGS

We then performed a retrospective analysis of RT-PCR results obtained using the TaqPath kit from August 3rd to December 20th by selecting only positive samples with a Ct value < 25 for the N target, the most sensitive target of the test. By doing so, we found that 59/9,266 (0.6%) of positive tests had no amplification of the S gene. No significant increase of the S negative profile was noticed over time; the proportion ranging from 0% (week # 32, 33, 34, 42, 48-51) to 2.91% (week # 35; Figure 2). Among the 59 samples without detection of the S target, 36 were available for WGS. These 36 samples were collected from August 5th to November 11th (18/36 were collected after October 9th). A total of 11 samples that presented an amplification of the S target were also sequenced. The sequencing results were fully concordant with the RT-PCR profiles (100% of the S negative profile had the S deletion ΔH69/ΔV70, while 100% of the S-positive profile did not contain ΔH69/ΔV70). For the S-negative samples, other S mutations were detected and are summarized in Table 1. The most frequent S mutations co-occurring with ΔH69/ΔV70 deletion were S477N and D614G that were found in 21/36 samples (58.3%). The co-occurrence of N439K and D614G mutations was found in 10/36 samples; the first sample containing this combination of mutation was collected in early

August. Most importantly, the complete combination of S mutations detected in VUI 202012/01 or in cluster- 5 variant was not found.

Discussion and conclusion

According to CoV-GLUE resource [8] (last update from GISAID: December 14th), the S deletion 21765-21770 has been identified in 4,632 sequences worldwide (>99% in Europe) Interestingly, only 16 sequences containing this deletion were sampled between March 15th and July 23th corresponding to the first wave of COVID-19 pandemic in Europe. Herein, using data obtained with TaqPath RT-PCR kit, we found an overall prevalence of 0.6%, suggesting a limited circulation of variants presenting the ΔH69/ΔV70 deletion during the second wave of the pandemic in Lyon, France.

It should be underlined that N439K, Y453F, or N501Y RBD mutations that can co-occurred with ΔH69/ΔV70 deletion might be associated with an increased affinity to ACE2 or reduced sensitivity to SARS-CoV-2 antibodies [3, 5, 10–12]. It has been hypothesized that the ΔH69/ΔV70 deletion might compensate some RBD mutations and might be involved in the transmissibility of variant containing these mutations [4, 6]. In addition, it has been recently shown that the combined ΔH69/V70 and D796H mutant was less sensitive to neutralizing antibodies [13]. As the N-terminal domain may interact with lung receptors [14] and might be a target of neutralizing antibodies [15, 16], further studies are needed to understand the consequences of ΔH69/ΔV70 deletion on SARS-CoV-2 transmissibility and host-immune response.

Importantly, the TaqPath kit used for this study did not lead to a false negative conclusion as the two other targets remain positive. The data presented herein emphasize that the TaqPath RT-PCR assay is a useful and cost-effective tool enabling a rapid, large-scale screening of ΔH69/ΔV70 variants. Samples with S negative profiles (negative for S target and positive for

N & ORF1ab targets) should be further addressed to national referral laboratories for SARS-CoV-2 WGS. This 2-step strategy can contribute to the early detection of SARS-CoV-2 variant of interest including VUI 202012/01 and is currently being reinforced in France as national diagnostic platforms have mainly implemented the TaqPath RT-PCR kit.

Spike mutation co-occurring with ΔH69/ΔV70 spike deletion	n (%)
S477N + D614G	21 (58.3%)
N439K + D614G	10 (27.8%)
H146Y + D614G	1 (2.78%)
D80Y + N439K + D614G	1 (2.78%)
ΔI670/Δ671/Δ672/Δ673 deletion + S477N + D614G	1 (2.78%)
D614G	1 (2.78%)
V401L + S477N + D614G	1 (2.78%)

Table 1. Spike mutations co-occurring with ΔH69/ΔV70 deletion in 36 samples with S negative profiles (negative for S target and positive for N & ORF1ab targets) obtained with the RT-PCR TaqPath kit.

Figure caption

Figure 1A. Amplification curves obtained with TaqPath COVID-19 RT-PCR kit for samples with the S deletion 21765-21770. The three targets included in the RT-PCR kit are represented by a different color. The amplification curve of the internal control is also represented (MS2, red curve). 1B. Pairwise sequence alignment from nucleotide position 21758 to 21775 of the spike gene using CoV-GLUE resource. Sequence with the deletion 21765-21770 is represented in green and the reference sequence in blue (Wuhan-Hu-1). The 21765-21770 deletion results in deletion of amino acid residues 69 and 70; ATC (21764-21771-21772) encoding for an isoleucine amino acid (I).

Figure 2. Prevalence of the S negative profile (negative for S target and positive for N & ORF1ab targets) with TaqPath COVID-19 RT-PCR kit from August 3rd (week 32) to December 20th (week 51).

References

1. ECDC to assess risk associated with spread of SARS-CoV-2 in mink farms. European Centre for Disease Prevention and Control. 2020. https://www.ecdc.europa.eu/en/news-events/ecdc-assess-risk-associated-spread-sars-cov-2-mink-farms. Accessed 8 Nov 2020.

2. WHO | SARS-CoV-2 mink-associated variant strain – Denmark. WHO. http://www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/. Accessed 25 Nov 2020.

3. Lassaunière Ria, Fonager Jannik, Rasmussen Morten, Frische Anders, Polacek Strandh Charlotta, Bruun Rasmussen Thomas, Bøtner Anette, Fomsgaard Anders. Working paper on SARS-CoV-2 spike mutations arising in Danish mink, their spread to humans and neutralization data.https://files.ssi.dk/Mink-cluster-5-short-report_AFO2.

4. Kemp SA, Datir RP, Collier DA, Ferreira I, Carabelli A, Harvey W, et al. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ΔH69/ΔV70. bioRxiv. 2020;:2020.12.14.422555.

5. Thomson EC, Rosen LE, Shepherd JG, Spreafico R, Filipe A da S, Wojcechowskyj JA, et al. The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity. bioRxiv. 2020;:2020.11.04.355842.

6. Andrew Rambaut, Nick Loman, Oliver Pybus, Wendy Barclay, Jeff Barrett, Alesandro Carabelli, Tom Connor, Tom Peacock, David L Robertson, Erik Volz, on behalf of COVID-19 Genomics Consortium UK (CoG-UK). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological. https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563/1. Accessed 21 Dec 2020.

7. Bal A, Destras G, Gaymard A, Bouscambert-Duchamp M, Valette M, Escuret V, et al. Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino acid deletion in nsp2 (Asp268del). Clin Microbiol Infect. 2020;26:960–2.

8. Singer J, Gifford R, Cotten M, Robertson D. CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation. 2020. doi:10.20944/preprints202006.0225.v1.

9. Charre C, Ginevra C, Sabatier M, Regue H, Destras G, Brun S, et al. Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation. Virus Evol. 2020;6:veaa075.

10. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9.

11. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–8.

12. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell. 2020;182:1295-1310.e20.

13. Kemp SA, Collier DA, Datir R, Gayed S, Jahun A, Hosmillo M, et al. Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion. medRxiv. 2020;:2020.12.05.20241927.

14. Soh WT, Liu Y, Nakayama EE, Ono C, Torii S, Nakagami H, et al. The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN. bioRxiv. 2020;:2020.11.05.369264.

15. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369:650–5.

16. McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G, et al. Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. bioRxiv. 2020;:2020.11.19.389916.

Data availability

SARS-CoV-2 whole genomes sequenced in this study were deposited in the GISAID database (EPI_ISL_582110, EPI_ISL_582111, EPI_ISL_582112, EPI_ISL_582113, EPI_ISL_582114, EPI_ISL_582115, EPI_ISL_582116, EPI_ISL_582117, EPI_ISL_582118, EPI_ISL_582119, EPI_ISL_582120, EPI_ISL_582508, EPI_ISL_623098, EPI_ISL_623099, EPI_ISL_623100, EPI_ISL_623101, EPI_ISL_623102)

Ethics statement

Samples used in this study were collected as part of an approved ongoing surveillance conducted by the national reference centre for respiratory viruses in Lyon, France (WHO reference laboratory providing confirmatory testing for COVID-19). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78–17 on 06/01/1978 and Décret 2019–536 on 29/05/2019). Samples were collected for regular clinical management during hospital stay, with no additional samples for the purpose of this study. Patients were informed of the research and their non-objection approval was confirmed. This study was presented by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N°41).

Acknowledgements

We would like to thank all microbiologist, clinicians, laboratory technicians who contributed to this investigation. We thank the authors, the originating and submitting laboratories for their sequence and metadata shared through GISAID on which this research is based. We gratefully acknowledge all the members of CoV-GLUE, Nextstrain.org, and virological.org for sharing their analysis in real-time. We thank Philip Robinson (DRCI, Hospices Civils de Lyon) for his help in manuscript preparation.

COVID-Diagnosis HCL Study Group

Jean-Sébastien Casalegno, Emilie Frobert, Vanessa Escuret, Vinca Icard, Marion Jeannoel, Marie-Paule Milon, Yahia Mekki, Christophe Ramière, Caroline Scholtès, Jean-Claude Tardy, Mary-Anne Trabaud, Isabelle Schuffenecker

1A


295,348.52
245,348.52
195,348.52
145,348.52
95,348.52
45,348.52
-4,651.48
Fluorescence
10
20
30
40
Cycle
ORF1ab
N Protein
S Protein
MS2 IPC

1B


66 67 68 69 70 71
H A I H V S
C A T G C T A T A C A T G T C T C T
21760
21770
H A S
C A T G C T A T C T C T


Number of positive samples
1500
1000
500
0
0%
0%
0%
2.78%
1.43%
2.84%
0.64%
1.23%
0.3%
0.15%
0%
0.44%
0.57%
0.99%
1.08%
1.23%
0%
0%
0%
0%
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
Week
Profile
S negative
S positive